US · Healthcare · Biotechnology
EPS came in at -0.26 against a street estimate of -0.60 — a beat of 56.7%.
Analysts rate Arcturus Therapeutics Holdings Inc a strong buy (11 buy, 2 hold, 0 sell out of 13) with an average price target of $23.80.
| Fund | Stake |
|---|---|
| Federated Hermes Inc | 11.62% |
| ARK Investment Management LLC | 10.21% |
| BlackRock Inc | 9.20% |
| Sumitomo Mitsui Trust Group Inc | 6.91% |
| Amova Asset Management Americas, Inc | 6.90% |
| Vanguard Capital Management, LLC | 3.92% |
| Two Sigma Investments LLC | 3.84% |
| Vanguard Portfolio Management, LLC | 3.35% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Arcturus Therapeutics Holdings Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.